
Please try another search
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
David P. Meeker | 71 | 2021 | Independent Non-Executive Chair |
Viviane Monges | 62 | 2021 | Non-Executive Director |
Elisabeth Bjork | 64 | 2021 | Non-Executive Director |
Robert Glassman | 63 | 2021 | Independent Non-Executive Director |
Berndt Axel Edvard Modig | 66 | 2015 | Co-Founder, CEO & Executive Director |
Hans J. G. C. P. Schikan | 67 | 2019 | Independent Vice Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review